Medical/Pharmaceuticals
Skyline Therapeutics Presents Late-Breaking Abstract on SKG1108, a Novel Optogenetic Gene Therapy for Retinitis Pigmentosa, at ASGCT 2025
SHANGHAI, May 10, 2025 /PRNewswire/ -- Skyline Therapeutics, an innovation-drivenclinical-stage gene therapy company focused on developing unique and novel solutions for rare and severe diseases, today announced a late-breaking abstract presentation onSKG1108, its investigational optogenetic gen...
2025-05-11 00:00
4615
Minghui Pharmaceutical Announces Strategic Partnership and Licensing Agreement with Qilu Pharmaceutical to Develop B7-H3 ADC in Greater China
SHANGHAI, May 9, 2025 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company, today announced an exclusive licensing and collaboration agreement with Qilu Pharmaceutical ("Qilu") for the development, manufacturing, and commercialization of its B7-H3 AD...
2025-05-09 18:00
8846
IASO Bio Receives Orphan Drug Designation from the Saudi Food and Drug Authority for Equecabtagene Autoleucel
SHANGHAI, NANJING, China and SAN FRANCISCO, May 9, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced that its self-developed BC...
2025-05-09 16:25
3521
Datasea Pre-Announces Estimated Third Quarter Revenue of approximately $51.9 Million, up approximately 164.6% Year-over-Year
Expects to Achieve Projected Annual Revenue of $90 Million BEIJING, May 8, 2025 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or "the Company"), aNevada-based digital technology company specializing in acoustics high-tech and 5G+AI multimodal digital innovations, today pre-announced its...
2025-05-08 21:30
5578
From Patient to Pioneer: jinIX Supports Nathan Ehrlich's Mission for Rare Disease Research
SAN FRANCISCO, May 8, 2025 /PRNewswire/ -- The
2025-05-08 20:35
2622
BioDlink Congratulates Junshi Biosciences on IND Approval of JS212, a Bispecific ADC Therapeutic Candidate
* BioDlink congratulates Junshi Biosciences on receiving IND approval from China's NMPA for JS212, the company's first bispecific ADC. * JS212 combines dual-targeting antibody technology with a cytotoxic payload, representing anext-generation therapeutic. * BioDlink provided end-to-end devel...
2025-05-08 20:30
5191
Penetrium™ Breaks Oncology Barriers: The Solution to Cold Tumors and Metastatic Cancer Unveiled at AACR 2025
* Penetrium™ Achieves Historic Breakthrough * Overcoming Cold Tumor Failure and the Challenge of Metastatic Cancer in Immunotherapy and Antibody Therapy * Presented at AACR 2025, Chicago CHICAGO, May 7, 2025 /PRNewswire/ -- Hyundai Bioscience presented the results of its Penetrium™ combinati...
2025-05-08 09:03
6518
Hanx Biopharmaceuticals, Ltd. Showcases Five Innovative Cancer Therapies at 2025 AACR Annual Meeting
CHICAGO, May 7, 2025 /PRNewswire/ -- Hanx Biopharmaceuticals Ltd. (HanxBio), a clinical-stage biotechnology company pioneering next-generation immunotherapies, highlighted its expanding oncology and autoimmune disease pipeline with five research poster presentations at the 2025 American Associat...
2025-05-07 21:30
2593
Lunit to Power Germany's Largest Private Radiology Network with AI Imaging
The five-year framework agreement covers phased rollout of Lunit's AI suite—including chest X-ray, mammography, tomosynthesis, and fracture detection—across 79 Starvision sites SEOUL, South Korea, May 7, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics ...
2025-05-07 21:00
3519
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids
* Primary Endpoint Met: Statistically significant reduction in heavy menstrual bleeding achieved in all dosage of Merigolix groups compared to placebo * Broader Therapeutic Potential: Positive Phase 2 results in both uterine fibroids and endometriosis could place Merigolix as a strong best-in...
2025-05-07 20:00
3126
CStone Presents Preclinical Results of CS2011 (EGFR/HER3 bispecific antibody), CS5007 (EGFR/HER3 bispecific ADC), CS5005 (SSTR2 ADC) and CS5006 (ITGB4 ADC) at 2025 AACR
SUZHOU, China, May 6, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on anti-cancer therapies, announced today that poster presentations of preclinical data of CS2011 (EGFR/HER3 bispecific antibody), CS5007 (EGFR/HER3 bis...
2025-05-07 08:00
3881
Formosa Pharmaceuticals Announces Licensing Agreement with Apotex Inc., for Commercialization of Clobetasol Propionate Ophthalmic Suspension for Post-Ocular Surgery Inflammation and Pain for Mexico
TAIPEI, May 6, 2025 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals (" Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Apotex Inc. ("Apotex"), for exclusive rights inMexico for the commercialization of clobetasol propionate ophthalmic...
2025-05-07 06:30
6440
Formosa Pharmaceuticals and Almac Discovery Announce Licensing Agreement for ALM-401, a First-in-Class Bispecific ADC targeting EGFR/ROR1 for the Treatment of Solid Tumors
TAIPEI, May 6, 2025 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced that the company has entered into an exclusive licensing agreement with Almac Discovery, aNorthern Ireland-based research driven drug discovery company, for exclusive rights to the commercializ...
2025-05-06 21:00
5800
SK bioscience Joins Korea's National Initiative to Develop Avian Influenza Vaccine Amid Rising Pandemic Threats
* Company aims to develop a bird flu vaccine with rapid mass production and variant responsiveness. * SK bioscience and KDCA join forces to build a national pandemic preparedness and response system for potential next-pandemic avian influenza. * "We will promote global public health and grow...
2025-05-06 20:00
3596
Fangzhou Launches Otsuka's Third-Generation Leukemia Drug Ponatinib on its Platform
GUANGZHOU, China, May 5, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced the availability of Otsuka Pharmaceutical's third-generation tyrosine kinase inhibitor (TKI) Iclusig® (ponatinib) through its online platform,...
2025-05-06 10:01
2912
Global First-in-Class AT2R Antagonist TRD205 Advances to Phase II: First Patient Dosed in Chronic Post-Surgical Neuropathic Pain Trial
BEIJING, May 5, 2025 /PRNewswire/ -- Beijing Tide Pharmaceutical Co., Ltd., a subsidiary of Sino Biopharmaceutical Limited (1177.HK), has achieved a milestone in developing its first-in-class analgesic drug (research code: TRD205), a highly selective angiotensin II type 2 receptor (AT2R) antagoni...
2025-05-06 07:00
2705
IND Application for NTS071, Nutshell Therapeutics' p53 Y220C Allosteric Reactivator, Received US FDA clearance
SHANGHAI, May 4, 2025 /PRNewswire/ -- On April 23, 2025, Nutshell Therapeutics ( Shanghai ) Co., LTD. received IND clearance from the FDA to initiate Phase 1 clinical trial inthe United States for its NTS071, a novel small molecule allosteric reactivator targeting p53 Y220C mutation. NTS07...
2025-05-04 14:48
4068
Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics
PHILADELPHIA, May 2, 2025 /PRNewswire/ -- Darnatein, a subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), a biotechnology company advancing design-augmented biologics, announced today that it will present scientific data at the14th International Bone Morphogenetic Protein (BMP) Conference, taking ...
2025-05-02 19:30
3579
AROA hits evidence milestone with real-world study validating the efficacy of Endoform in treating challenging venous leg ulcers.
AUCKLAND, New Zealand, May 1, 2025 /PRNewswire/ -- Soft tissue regeneration
company, Aroa Biosurgery, is pleased to announce a milestone in clinical
evidence.
2025-05-02 10:42
5036
FaceHeart Received Another FDA Clearance for its Contactless Video-Based Vital Sign Measurement of Respiratory Rate
* Developed by FaceHeart, FH Vitals SDK-RR has obtained FDA Clearance. This is the second 510(k) class II SaMD (Software as a Medical Device) FaceHeart received from the FDA. * FaceHeart Vitals™ is a video-based, contactless vital sign measurement SDK that can be integrated into devices such ...
2025-05-01 23:06
4086
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 275 media titles]
2026-10-09 13:21CHANDO Group Presents 20 Research Papers at IFSCC 2026 Congress in Perth
[Picked up by 263 media titles]
2026-10-06 11:40
Most Read
DayOne Files Registration Statement for Proposed Initial Public Offering
2026-10-06 05:28
10084
Nuix Neo Generative AI Framework
2026-10-08 08:02
10048
Silicon Quantum Computing Named to Fast Company's 2026 Next Big Things in Tech List
2026-10-06 19:38
9196
